Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Novelion Therapeutics Inc (NQ: NVLN )

0.6800 USD UNCHANGED
Last Price Updated: 4:35 PM EDT, Oct 8, 2019 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Novelion Therapeutics Inc

< Previous 1 2 Next >
Novelion Therapeutics Announces Nasdaq Delisting
From GlobeNewswire News Releases
Novelion Therapeutics Announces Filing of Definitive Proxy Statement in Connection with Proposed Liquidation and Other Matters
From GlobeNewswire News Releases
Novelion Therapeutics Announces Completion of Aegerion Transaction and Departure of Certain Directors and Officers
From GlobeNewswire News Releases
Novelion Therapeutics Announces US Court Confirmation of Aegerion Bankruptcy Case, Update on Nasdaq Delisting and Date of Annual General Meeting of Shareholders
From GlobeNewswire News Releases
Novelion Therapeutics Provides Update Regarding Delisting from Nasdaq and Aegerion Bankruptcy Case
From GlobeNewswire News Releases
Novelion Therapeutics Announces Issuance of General Cease Trade Order in Canada and Notice of Delisting from Nasdaq
From GlobeNewswire News Releases
Novelion Therapeutics Announces Anticipated Late Filing of Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2019
From GlobeNewswire News Releases
Novelion Therapeutics Announces Dismissal of Whitefort Capital Petition
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that on... 
From GlobeNewswire News Releases
Novelion Therapeutics Receives Delisting Notifications
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, announced that on July 3, 2019,... 
From GlobeNewswire News Releases
Novelion Therapeutics Responds to Whitefort Capital Petition
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that on... 
From GlobeNewswire News Releases
Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion
Novelion Therapeutics Inc. (NASDAQ: NVLN) (Novelion), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that its... 
From GlobeNewswire News Releases
Novelion Therapeutics Reports First Quarter 2019 Financial Results
Company reiterates 2019 guidance of total net revenues between $160.0 and $175.0 million, including approximately $30.0 million of licensing revenues 
From GlobeNewswire News Releases
Novelion Therapeutics Observes World Lipodystrophy Day
Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, in association with its subsidiary... 
From GlobeNewswire News Releases
Novelion Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”),... 
From GlobeNewswire News Releases
Novelion Therapeutics Observes Rare Disease Day
Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases 
From GlobeNewswire News Releases
Paramount Developments Crucial for Advancing Clinical Trials Targeting Cancer Treatments
Financialnewsmedia.com News Commentary 
From PR Newswire
Paramount Developments Crucial for Advancing Clinical Trials Targeting Cancer Treatments
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that its... 
From GlobeNewswire News Releases
Stimulated Development of Orphan Drug Designations for Rare Diseases and Anti-Cancer Drug Candidates Intensifies
Financialnewsmedia.com News Commentary 
From PR Newswire
Stimulated Development of Orphan Drug Designations For Rare Diseases and Anti-Cancer Drug Candidates Intensifies
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Novelion Therapeutics Announces Leadership Change
Novelion Therapeutics Inc. (NASDAQ:NVLN), today announced that General Counsel, Benjamin Harshbarger, has been appointed as interim CEO, reporting to Novelion’s Executive Chair, Mark Corrigan, M.D.,... 
From GlobeNewswire News Releases
Is it time to buy stock in Aurora Cannabis Inc, Advanced Micro Devices, General Electric, Novelion Therapeutics or Tesla Inc.?
InvestorsObserver issues critical PriceWatch Alerts for ACB, AMD, GE, NVLN, and TSLA. 
From PR Newswire
Thinking about buying stock in Advanced Micro Devices, ARRIS Group Inc., General Electric, Novelion Therapeutics or Square Inc.?
InvestorsObserver issues critical PriceWatch Alerts for AMD, ARRS, GE, NVLN, and SQ. 
From PR Newswire
Novelion Therapeutics Reports Third Quarter 2018 Financial Results
Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”),... 
From GlobeNewswire News Releases
Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that its... 
From GlobeNewswire News Releases
Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today its observance of The FH... 
From GlobeNewswire News Releases
Novelion Therapeutics Announces Next Phase of Operational Improvements
Once fully implemented, plans expected to reduce annual costs by approximately $35 million 
From GlobeNewswire News Releases
Novelion Therapeutics Reports Second Quarter 2018 Financial Results
Following recent marketing approval in both generalized and partial lipodystrophy indications, European launch of MYALEPTA® has commenced 
From GlobeNewswire News Releases
Novelion Therapeutics Announces Marketing Authorization for MYALEPTA® (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy
MYALEPTA is the first approved therapy in Europe indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients 
From GlobeNewswire News Releases
Novelion Therapeutics Appoints Mark Corrigan, M.D. as Executive Chair of the Board of Directors
Chief Operating Officer Jeff Hackman Appointed as Interim Chief Executive Officer (CEO) 
From GlobeNewswire News Releases
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.